United States · Markets & Finance · Yahoo Finance

Where Will Eli Lilly Stock Be in 5 Years? Follow the Pipeline Beyond Zepbound

Published by Yahoo Finance · United States 10 h ago

Continue » Eli Lilly's Zepbound is currently the leading medicine in the anti-obesity market largely because it is more effective than its main competitor, Novo Nordisk 's (NYSE:…

Read the full article on Yahoo Finance Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finance.yahoo.com)

Also worth reading

Business Insider

David Robinson says a sense of 'cognitive dissonance' led him to leave OpenAI

Quartz

The 5 most expensive basketball cards ever sold

Seeking Alpha

Wall Street closed in the red as investors focused on yields and the Fed minutes

OilPrice.com

Global Diesel Crunch Fuels New Wave of Energy Nationalism

Decrypt

Tether Signs Deal With Kazakhstan's Central Bank to Explore a Stablecoin and Tokenized Assets

CNBC